Phase Forward

Oracle to Acquire Phase Forward for $685M

Friday, April 16, 2010 02:37 PM

Business software giant Oracle, already a player in the eClinical space, plans to acquire market leader Phase Forward in a deal valued at approximately $685 million—or $17 per share in cash.

More... »


’09 Acquisitions Bring Phase Forward Revenues Up, Profits Down

Friday, February 5, 2010 10:19 AM

Phase Forward’s fourth quarter revenues jumped 22% but profits went down, the company reported Thursday night. Phase Forward’s share price was down 26.7% to $10.88 in early morning trading.

More... »


Phase Forward Appoints First Chief Privacy Officer

Thursday, December 24, 2009 07:40 AM

Phase Forward appointed long-time employee Michael Owings to the new role of chief privacy officer. Owings will oversee all privacy and data protection processes affecting Phase Forward’s customers and employees, and ensure compliance with all relevant regulations. He will also continue his duties as vice president, quality and regulatory compliance—a title he’s held since 2004.

More... »

Phase Forward Q3 Revenues Jump 24%, Earnings Down by Half

Friday, October 30, 2009 09:11 AM

Waltham, Mass-based Phase Forward, a provider of data management solutions for clinical trials and drug safety, reported third quarter revenues jumped 24% to $53.1 million, compared with the third quarter of 2008, but earnings were cut in half.

More... »

Phase Forward Provides Free Download for CDISC Adopters

Thursday, October 29, 2009 09:04 AM

Phase Forward, a provider of data management solutions for clinical trials and drug safety, released its DefineValidator tool, Release 1.0, as a free download for Clinical Data Interchange Standards Consortium (CDISC) adopters.

More... »

Phase Forward Receives SCDM Award

Friday, October 23, 2009 07:13 AM

The Society for Clinical Data Management has awarded its annual Data Driven Innovation Award to Phase Forward for developing a technology that increased external data loading rates 100-fold.

More... »

Phase Forward, Gedeon Richter in Multi-year Deal

Tuesday, October 13, 2009 06:42 AM

Phase Forward, a provider of data management solutions for clinical trials and drug safety, signed a multi-year agreement with Gedeon Richter, one of Central-Eastern Europe’s leading pharmaceutical companies with more than 10,000 employees worldwide.

More... »

SGS Partnership Helps Phase Forward Advance Business Strategy

Monday, August 24, 2009 06:50 AM

Phase Forward’s recent multi-million-dollar agreement with Swiss contract research organization (CRO) SGS Life Science Services not only provides the stability of a long-term contract to Phase Forward but also helps the eClinical provider advance its core strategy.

More... »

Phase Forward to Acquire Maaguzi for $11M, Profits Down in Q2

Tuesday, July 28, 2009 03:09 PM

Within days of announcing the pending acquisition of Covance’s interactive voice and web response business, eClinical company Phase Forward announced Monday it has purchased technology company Maaguzi for $11 million cash.

More... »

Phase Forward Agrees to $10M Acquisition, Multi-Year Partnership with Covance

Wednesday, July 15, 2009 01:30 PM

Covance is selling its interactive voice and web response services (IVR/IWR) business to eClinical provider Phase Forward for $10 million cash, and the two companies have entered into a multi-year agreement making Phase Forward a preferred provider for the contract research organization (CRO).

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs